Company Information

Company Profile

Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.

Latest Presentations

Presentation

Contact Information

Investor Relations
Avalo Therapeutics
ir@avalotx.com